The following discussion and analysis should be read in conjunction with our unaudited financial statements and the notes to those financial statements that are included elsewhere in this Form 10-Q. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. We use words such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," "predict," and similar expressions to identify forward-looking statements. Any statement contained in this report that is not a statement of historical fact may be deemed to be a forward-looking statement. Although we believe that the plans, objectives, expectations and prospects reflected in or suggested by our forward-looking statements are reasonable, those statements involve risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements, and we can give no assurance that our plans, objectives, expectations and prospects will be achieved..





Overview

We were incorporated as "Alternative Energy & Environmental Solutions, Inc." in the State of Nevada on June 10, 2010, to develop and license an innovative biotechnology for the environmentally friendly and cost-effective extraction of natural gas (coalbed methane) from low-producing, depleted and abandoned coal mines in the U.S. We were not successful in developing that business and discontinued its biotechnology related operations. We changed our name in 2014 to Unique Growing Solutions, Inc. and again in 2015 to Point of Care Nano-Technology, Inc.

On February 25, 2015, we entered into a license agreement with Lamina Equities Corporation ("Lamina"), to license intellectual property for diagnosing illness in humans via a saliva test. During the past few years, we have not had the financial resources to pursue business development relating to the Lamina license.

Our plan of operation for the next 12 months is to seek and acquire new business assets in the life sciences industry and begin operations with these new assets. We also plan to split off the Lamina license although at this time we are not sure when we will complete this split-off, if at all. We cannot make any guarantee that we will be successful in achieving our new operational objectives.





RESULTS OF OPERATIONS

Comparison of Three Months Ended January 31, 2022 and 2021





Revenues

Our total revenue was $0 for the three-month periods ended January 31, 2022 and 2021, respectively.





Cost of Goods Sold

Our cost of goods sold was $0 for the three-month periods ended January 31, 2022 and 2021, respectively.

Operating Expenses (including Selling, General and Administrative Expenses)

For the three months ended January 31, 2022, our operating expenses increased to $13,795 from $0 for the three months ended January 31, 2021. The increase was primarily due to increased consulting, legal, filing and investor expenses.





Net Other Income (Expense)

Our net other income (expenses) was $0 for the three-month periods ended January 31, 2022 and 2021, respectively.



                                       10



Income Tax Expense

Income tax expense was $0 and $0 for the three-month period ended January 31, 2022 and 2021, respectively.





Net Loss

As a result of the foregoing factors, we had a net loss of $13,795 for the three months ended January 31, 2022, as compared to $0 for the three months ended January 31, 2021.

Comparison of Six Months Ended January 31, 2022 and 2021





Revenues

Our total revenue was $0 for the six-month periods ended January 31, 2022 and 2021.

Operating Expenses (including Selling, General and Administrative Expenses)

For the six months ended January 31, 2022, the Company's Operating Expense increased to $56,050 from $0 for the six months ended January 31, 2021. The increase was primarily due to increased consulting, legal, filing and investor expenses.





Net Other Income (Expense)

For the six months ended January 31, 2022, the Company had Net Other Income (Expense) of $-0- compared to Net Other Expenses of $-0- for the six months ended January 31, 2021.





Income Tax Expense

Income tax expense was $0 and $0 for the six-month period ended January 31, 2022 and 2021, respectively.





Net Loss

As a result of the foregoing factors, we had a net loss of $56,050 for six months ended January 31, 2022, as compared to $0 for the six months ended January 31, 2021.

LIQUIDITY AND CAPITAL RESOURCES

At January 31, 2022, we had $0 in cash, compared to $0 at October 31, 2021. At January 31, 2022, our accumulated stockholders' deficit was $120,268,417 compared to $120,212,367 at July 31, 2021. There is substantial doubt as to our ability to continue as a going concern.

The Company has had no cash flow for the two years ended July 31, 2021 and 2020 and subsequent quarters. In the future, the Company's cash flow will depend on the timely and successful market entry of the Company's expected strategic offerings.

© Edgar Online, source Glimpses